BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36378538)

  • 21. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
    Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
    Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
    Takahashi S; Tahara M; Ito K; Tori M; Kiyota N; Yoshida K; Sakata Y; Yoshida A
    Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clear Cell Variant of Papillary Thyroid Carcinoma With Associated Anaplastic Thyroid Carcinoma: Description of an Extraordinary Case.
    Juhlin CC; Höög A
    Int J Surg Pathol; 2019 Sep; 27(6):658-663. PubMed ID: 30931661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer.
    Fan D; Ma J; Bell AC; Groen AH; Olsen KS; Lok BH; Leeman JE; Anderson E; Riaz N; McBride S; Ganly I; Shaha AR; Sherman EJ; Tsai CJ; Kang JJ; Lee NY
    Cancer; 2020 Jan; 126(2):444-452. PubMed ID: 31593317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
    Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma.
    Tiedje V; Ting S; Herold T; Synoracki S; Latteyer S; Moeller LC; Zwanziger D; Stuschke M; Fuehrer D; Schmid KW
    Oncotarget; 2017 Jun; 8(26):42613-42620. PubMed ID: 28489587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment and characterization of a new patient-derived anaplastic thyroid cancer cell line (C3948), obtained through fine-needle aspiration cytology.
    Pinto AT; Pojo M; Simões-Pereira J; Roque R; Saramago A; Roque L; Martins C; André S; Cabeçadas J; Leite V; Cavaco BM
    Endocrine; 2019 Nov; 66(2):288-300. PubMed ID: 31368081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.
    Molinaro E; Romei C; Biagini A; Sabini E; Agate L; Mazzeo S; Materazzi G; Sellari-Franceschini S; Ribechini A; Torregrossa L; Basolo F; Vitti P; Elisei R
    Nat Rev Endocrinol; 2017 Nov; 13(11):644-660. PubMed ID: 28707679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutation based approaches to the treatment of anaplastic thyroid cancer.
    McCrary HC; Aoki J; Huang Y; Chadwick B; Kerrigan K; Witt B; Hunt JP; Abraham D
    Clin Endocrinol (Oxf); 2022 May; 96(5):734-742. PubMed ID: 35067961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of Entrectinib in a Patient With the First Reported
    Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis.
    Kim SY; Kim SM; Kim JW; Lee IJ; Jeon TJ; Chang H; Kim BW; Lee YS; Chang HS; Park CS
    Front Endocrinol (Lausanne); 2020; 11():599. PubMed ID: 32982983
    [No Abstract]   [Full Text] [Related]  

  • 32. Conversion surgery after lenvatinib treatment for anaplastic thyroid carcinoma: a case report.
    Yamazaki H; Masudo K; Kanada S; Inayama Y; Hayashi H; Fujii Y; Rino Y
    Surg Case Rep; 2023 Mar; 9(1):38. PubMed ID: 36920674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
    Delgado J; Pean E; Melchiorri D; Migali C; Josephson F; Enzmann H; Pignatti F
    ESMO Open; 2021 Apr; 6(2):100087. PubMed ID: 33735800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF
    Zhao X; Wang JR; Dadu R; Busaidy NL; Xu L; Learned KO; Chasen NN; Vu T; Maniakas A; Eguia AA; Diersing J; Gross ND; Goepfert R; Lai SY; Hofmann MC; Ferrarotto R; Lu C; Gunn GB; Spiotto MT; Subbiah V; Williams MD; Cabanillas ME; Zafereo ME
    Thyroid; 2023 Apr; 33(4):484-491. PubMed ID: 36762947
    [No Abstract]   [Full Text] [Related]  

  • 35. Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET/CT: A case report.
    Giannetta E; Isidori AM; Durante C; Di Gioia C; Longo F; Tombolini V; Bulzonetti N; Graziadio C; Pofi R; Gianfrilli D; Verrienti A; Carletti R; Filetti S; Lenzi A; Baroli A
    Medicine (Baltimore); 2017 Feb; 96(6):e5621. PubMed ID: 28178124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in
    Smith KM; Fagan PC; Pomari E; Germano G; Frasson C; Walsh C; Silverman I; Bonvini P; Li G
    Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients.
    Sugitani I; Miyauchi A; Sugino K; Okamoto T; Yoshida A; Suzuki S
    World J Surg; 2012 Jun; 36(6):1247-54. PubMed ID: 22311136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metastasis to Stomach in a Patient with Anaplastic Thyroid Carcinoma: A Clinical Challenge.
    Fuladi R; Nagarkar R; Roy S
    Am J Case Rep; 2019 Feb; 20():134-138. PubMed ID: 30705249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
    Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
    Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer.
    Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG
    J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.